Back to News
Market Impact: 0.25
SueWallSt Reminds Aardvark Therapeutics Investors of the Pending Class Action Lawsuit With a Lead Plaintiff Deadline of October 13, 2026
Source: globenewswire.com
Legal & LitigationHealthcare & Biotech
A securities class-action lawsuit has been filed against Aardvark Therapeutics on behalf of investors who purchased AARD shares between February 13, 2025 and May 14, 2026. The notice provides no allegations, claimed damages, or potential financial exposure, but the litigation introduces legal and reputational risk for the biotech company.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
moderately negative
Sentiment Score
-0.45
Ticker Sentiment
AARD-0.85
More News
- Looters hit 3,000 French businesses. Within hours, the haul was trending on Vinted under the riot’s date
- Vertex reports positive IgAN trial data, FDA decision due Nov. 30
- The real test for Moderna’s cancer vaccine isn’t about beating Keytruda. It’s keeping cancer from coming back in the long term.
- J&J prostate cancer drug shows promising tumor responses in early trial
- Exclusive-Boeing supplier dispute has halted 777 freighter production for two months, sources say
- Meta shares are down 9% this week. Here's why Mike Khouw is buying now
From AllMind Research
- Anthropic IPO Preview: Valuation, Timing, and What to Watch
- Shein After the IPO: Venue, Valuation, and What Must Be Proved
- What AI Research Tools Should a Small Hedge Fund Buy First?
- AlphaSense vs Hebbia vs AllMind: Choose by Workflow
- AllMind Discusses Ontario's AI Economy with Minister Stephen Crawford and Supply Ontario CEO James Wallace